Ovagen
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Ovagen is a Khavinson tripeptide the source directory profiles for liver and GI tissue — hepatocyte function and GI mucosal health. Despite the name, it is not an ovarian-tissue peptide. It’s part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Livagen.
What does it do in my body?
Claimed mechanism: like the rest of the Khavinson family, Ovagen is proposed to modulate gene expression in a tissue-specific way — here, supporting hepatocyte function and GI mucosal integrity. There is no Ovagen-specific mechanistic study to cite beyond the general family-level theoretical claim.
How can it help me?
- Where the science stands: Directory lists “Emerging” (22 studies, 1 human) — but all 22 are a name-collision with veterinary superovulation literature, not real peptide evidence. Actual base: effectively empty, framework-level only
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-event data exists for Ovagen specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Ovagen’s name-collision problem makes it a particularly good case study for why citation verification matters — a seller citing “22 studies” for this peptide is citing the wrong literature entirely. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Ovagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Ovagen — the 22 “citations” are not real peptide evidence, so there is no dose-finding work to draw on. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Ovagen specifically.
What should I avoid combining — and what's synergistic?
Ovagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
Ovagen is available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
Ovagen is a Khavinson tripeptide for liver and GI tissue — despite the name, NOT ovarian tissue. The 22 citations the source directory attaches to it are a name-collision with bovine/ovine/caprine superovulation veterinary literature, not real evidence for this peptide. Read that correction first; it’s the honesty-critical fact about this compound.
| Class | Khavinson tripeptide — sequence; targets liver and GI tissue |
| Mechanism (one line) | Claimed to support hepatocyte function and GI mucosal health via the family’s gene-modulation mechanism |
| Evidence base | Directory lists “Emerging” (22 studies, 1 human) — but all 22 are a name-collision with veterinary superovulation literature, not real peptide evidence. Actual base: effectively empty, framework-level only |
| Safety record | No AE data specific to Ovagen; family-wide mild profile assumed; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Ovagen is a Khavinson tripeptide the source directory profiles for liver and GI tissue — hepatocyte function and GI mucosal health. Despite the name, it is not an ovarian-tissue peptide. It’s part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Livagen.
How it works
Claimed mechanism: like the rest of the Khavinson family, Ovagen is proposed to modulate gene expression in a tissue-specific way — here, supporting hepatocyte function and GI mucosal integrity. There is no Ovagen-specific mechanistic study to cite beyond the general family-level theoretical claim.
What the research shows
Important source caveat. The 22 studies the directory attaches to Ovagen are all bovine/ovine/caprine superovulation and embryo-production papers (FSH, follicular dynamics in ewes and beef cows) — a clear name-collision between “Ovagen” the Khavinson liver peptide and “ovagen/ovulation” veterinary reproduction literature that the directory auto-matched. None of those citations are evidence for the Ovagen peptide.
The honest read: the Ovagen peptide’s actual human/preclinical evidence base is effectively empty; treat it as framework-level only, like Livagen. Flagged and corrected here rather than repeated. (This name-collision is also why the peptide gets grouped under both “digestive” and “reproductive” in some build materials — the name straddles both, but the peptide is the liver/GI one.)
OHM grade: D / provisional.
Real-world protocol
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Ovagen — the 22 “citations” are not real peptide evidence, so there is no dose-finding work to draw on. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Ovagen specifically.
Side effects & management
No adverse-event data exists for Ovagen specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Ovagen’s name-collision problem makes it a particularly good case study for why citation verification matters — a seller citing “22 studies” for this peptide is citing the wrong literature entirely. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Ovagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Ovagen kept D-provisional / encyclopedia-only.
- Note: the directory’s 22 cited studies are bovine/ovine/caprine superovulation veterinary literature — a name-collision, not evidence for this peptide (flagged, not itemized as citations here).
- Related: Pancragen · Livagen · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Ovagen kept D-provisional / encyclopedia-only.
- Note: the directory’s 22 cited studies are bovine/ovine/caprine superovulation veterinary literature — a name-collision, not evidence for this peptide (flagged, not itemized as citations here).
- Related: Pancragen · Livagen · the Khavinson bioregulator family.